AdaptHealth (NASDAQ:AHCO) Stock Price Target Cut by UBS Group

Key Points

• UBS lowered AdaptHealth’s price target from $10 to $9 but maintained its Buy rating; the new target implies 23.12% upside from the share price cited in the article.
• Analyst sentiment remains broadly positive: MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $10.
• AdaptHealth reported a quarterly loss of $1.13 per share, far worse than the $0.05 loss analysts expected. Revenue beat estimates at $745.65 million but fell 9.1% year over year.

AdaptHealth (NASDAQ:AHCO - Get Free Report) had its price objective decreased by research analysts at UBS Group from $10.00 to $9.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a "buy" rating on the stock. UBS Group's price objective would suggest a potential upside of 23.12% from the stock's current price.

Other equities analysts also recently issued reports about the stock. Truist Financial decreased their price target on shares of AdaptHealth from $14.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, August 5th. Robert W. Baird reduced their price target on AdaptHealth from $10.00 to $9.00 and set an "outperform" rating on the stock in a research report on Thursday, September 17th. Canaccord Genuity Group set a $10.00 price target on AdaptHealth in a research report on Wednesday, August 5th. Weiss Ratings reissued a "sell (d)" rating on shares of AdaptHealth in a report on Wednesday, August 19th. Finally, Jefferies Financial Group raised shares of AdaptHealth from a "hold" rating to a "buy" rating and upped their price objective for the stock from $11.00 to $13.00 in a research report on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AdaptHealth has a consensus rating of "Moderate Buy" and an average price target of $10.00.

AdaptHealth Stock Performance

Shares of AHCO traded up $1.03 during trading hours on Wednesday, hitting $7.31. The company had a trading volume of 6,327,405 shares, compared to its average volume of 1,945,419. The firm has a market cap of $996.65 million, a price-to-earnings ratio of -4.27 and a beta of 1.36. The company has a quick ratio of 0.98, a current ratio of 1.12 and a debt-to-equity ratio of 1.37. The business has a fifty day moving average of $5.90 and a 200-day moving average of $9.12. AdaptHealth has a 12 month low of $5.21 and a 12 month high of $13.43.

AdaptHealth (NASDAQ:AHCO - Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($1.08). AdaptHealth had a negative net margin of 7.07% and a positive return on equity of 3.36%. The company had revenue of $745.65 million during the quarter, compared to the consensus estimate of $725.87 million. During the same period in the prior year, the company earned $0.16 earnings per share. The firm's revenue was down 9.1% compared to the same quarter last year.

Insiders Place Their Bets

In other AdaptHealth news, Director Kenneth Samet purchased 23,500 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was purchased at an average price of $6.38 per share, with a total value of $149,930.00. Following the completion of the purchase, the director owned 48,569 shares of the company's stock, valued at approximately $309,870.22. The trade was a 93.74% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.95% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AdaptHealth

A number of institutional investors have recently modified their holdings of AHCO. Fulcrum Asset Management LLP increased its stake in shares of AdaptHealth by 526.4% in the 3rd quarter. Fulcrum Asset Management LLP now owns 24,456 shares of the company's stock valued at $139,000 after acquiring an additional 20,552 shares in the last quarter. Brickley Wealth Management bought a new stake in AdaptHealth in the 3rd quarter valued at about $56,000. Brighton Jones LLC bought a new position in AdaptHealth in the third quarter worth approximately $125,000. Chicago Partners Investment Group LLC acquired a new stake in AdaptHealth in the third quarter valued at approximately $118,000. Finally, State of Wyoming grew its position in AdaptHealth by 126.4% in the 3rd quarter. State of Wyoming now owns 51,913 shares of the company's stock valued at $293,000 after purchasing an additional 28,988 shares during the period. 82.67% of the stock is owned by institutional investors.

AdaptHealth News Summary

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: AdaptHealth raised its 2026 adjusted EBITDA guidance to $510 million–$525 million and outlined a path to a 20% margin on its largest capitated contract by Q4 2027. The improved outlook and potential contract profitability are positive signals for investors. AdaptHealth margin and outlook article
• Positive Sentiment: Third-quarter revenue of $745.65 million topped analysts’ $725.87 million estimate, providing a bright spot in the earnings report. Third-quarter results
• Neutral Sentiment: The company will participate in the UBS Global Healthcare Conference on November 10. The event may provide investors with further details, but the announcement itself does not indicate a change in business performance. Investor conference announcement
• Negative Sentiment: AdaptHealth reported a third-quarter loss of $1.13 per share, substantially worse than the $0.05 loss analysts expected. Revenue was also down 9.1% year over year, highlighting ongoing performance challenges despite the estimate beat. Quarterly earnings report

About AdaptHealth

AdaptHealth Corp. NASDAQ: AHCO is a provider of home medical equipment, supplies and related healthcare services in the United States. The company helps patients manage chronic conditions and recover from illness or injury outside of traditional healthcare facilities, working with individuals, caregivers, physicians and payers.

Its products and services include respiratory equipment and supplies, oxygen therapy, sleep therapy devices such as continuous positive airway pressure systems, diabetes management products, mobility and accessibility equipment, and other durable medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.